Carboxypeptidasen, Carboxypeptidases, Chymase, Mast cells, Mastzellen, Melanom, Melanoma, Tryptase
Atiakshin D, et al. Protease Profile of Tumor-Associated Mast Cells in Melanoma. Int J Mol Sci 2022 Aug 11;23(16):8930. doi:10.3390/ijms23168930
Chemical Biology, Chemische Biologie, Drug Development, Medikamentenentwicklung, Pentafluorophosphate, Pentafluorophosphates, Phosphotyrosin Biomimetica, Phosphotyrosine Biomimetics, Protein Tyrosin Phosphatasen, Protein Tyrosine Phosphatases
Accorsi M, et al. Pentafluorophosphato-Phenylalanines: Amphiphilic Phosphotyrosine Mimetics Displaying Fluorine-Specific Protein Interactions. Angew Chem Int Ed Engl 2022 Jun 20;61(25):e202203579. doi:10.1002/anie.202203579
Carboxypeptidase A3, Granula, granules, Mast cells, Mastzellen, secretome, secretory pathways, Sekretom, Sekretorische Signalwege, Specific tissue microenvironment, spezifisches Gewebemikromilieu
Atiakshin D, et al. Carboxypeptidase A3-A Key Component of the Protease Phenotype of Mast Cells. Cells 2022 Feb 6;11(3):570. doi:10.3390/cells11030570
EGFR, metastasiert, metastatic, non small cell lung cancer (NSCLC), NSCLC, Osimertinib, TP53 co-mutation, TP53 Komutation
Roeper J, et al. TP53 co-mutations as an independent prognostic factor in 2nd and further line therapy- EGFR mutated non-small cell lung cancer IV patients treated with osimertinib. Transl Lung Cancer Res 2022 Jan;11(1):4-13. doi:10.21037/tlcr-21-754
Paitazoglou C, Bergmann MW, Tiemann K, et al. Atrial Giant Cell Myocarditis as a Cause of Heart Failure: Diagnostic Pathway and Successful Treatment. JACC Case Rep. 2022 Jan 5;4(1):66-71. doi:10.1016/j.jaccas.2021.11.007
Malapelle U, Tiseo M, Vivancos A, Kapp J, Serrano MJ, Tiemann M. Liquid Biopsy for Biomarker Testing in Non-Small Cell Lung Cancer: A European Perspective. J. Mol. Pathol. 2021 Aug 18;2(3):255-273. doi:10.3390/jmp2030022
Hoffmann C, Tepel J, Tiemann M. Morbus Castleman – ein seltenes, heterogenes Krankheitsbild. Best Practice Onkologie 2021 Mar 09;16:198-206. doi:10.1007/s11654-021-00300-4
